Lineage Cell Therapeutics, Inc.
LCTX- Exchange
- NYSE
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0000876343
No open-market purchases or sales by Lineage Cell Therapeutics, Inc. insiders were filed in the last 90 days; 131 institutions reported holding it in 13F filings for Q2 2026, worth $152.7M in total; no superinvestor holds it.
13F holders, Q4 2024
Institutional positions in Lineage Cell Therapeutics, Inc. as of Dec 31, 2024. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 126
- +15 vs. Q3 2024
- Shares held
- 107.1M
- +12.6M (+13.3%) vs. Q3 2024
- Total value
- $53.8M
- −$31.7M (−37.1%) vs. Q3 2024
- New holders
- 28
- 38 more added
- Sold out
- 13
- 16 more reduced
3 institutions that held it in Q3 2024 haven't filed for Q4 2024 yet. Not filing isn't selling, so they aren't counted as sold out or in the changes above.
Compare with Q3 2024: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting LCTX on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 131 | $152.7M |
| Q1 2026 | 130 | $176.5M |
| Q4 2025 | 123 | $169.8M |
| Q3 2025 | 112 | $148.6M |
| Q2 2025 | 129 | $88.4M |
| Q1 2025 | 127 | $49.7M |
| Q4 2024 | 126 | $53.8M |
| Q3 2024 | 114 | $85.6M |
| Q2 2024 | 113 | $94.2M |
| Q1 2024 | 116 | $138.3M |
| Q4 2023 | 115 | $82.5M |
| Q3 2023 | 104 | $89.1M |
| Q2 2023 | 107 | $106.6M |
| Q1 2023 | 116 | $104.7M |
| Q4 2022 | 106 | $76.2M |
| Q3 2022 | 104 | $73.1M |
| Q2 2022 | 100 | $102.7M |
| Q1 2022 | 109 | $112.3M |
| Q4 2021 | 124 | $182.0M |
| Q3 2021 | 115 | $191.7M |
| Q2 2021 | 115 | $208.5M |
| Q1 2021 | 102 | $141.8M |
Institutions, Q4 2024
Shares, value and share of portfolio for each institution holding Lineage Cell Therapeutics, Inc.; share changes are against Q3 2024.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Two Sigma Investments, LP | 301,544 | $151.5K | 0.00% | +301,544 | New |
| Bank of New York Mellon Corp | 337,827 | $169.8K | 0.00% | +1100.0% | Added |
| Red Crane Wealth Management, LLC | 340,236 | $171.0K | 0.16% | +340,236 | New |
| Goldman Sachs Group Inc | 385,066 | $193.5K | 0.00% | +140,842+57.7% | Added |
| Prescott General Partners LLC | 386,000 | $194.0K | 0.01% | 00.0% | Unchanged |
| Gsa Capital Partners LLP | 408,837 | $205.0K | 0.02% | +315,805+339.5% | Added |
| Charles Schwab Investment Management Inc | 416,223 | $209.2K | 0.00% | 00.0% | Unchanged |
| Bridgeway Capital Management, LLC | 417,900 | $210.0K | 0.00% | −338,866−44.8% | Reduced |
| Nuveen Asset Management, LLC | 515,445 | $259.0K | 0.00% | 00.0% | Unchanged |
| MAI Capital Management | 657,679 | $330.5K | 0.00% | −1,017,000−60.7% | Reduced |
| Morgan Stanley | 660,061 | $331.7K | 0.00% | −188,230−22.2% | Reduced |
| Comerica Bank | 800,000 | $402.0K | 0.00% | +550,000+220.0% | Added |
| JPMorgan Chase & Co | 946,399 | $475.6K | 0.00% | +269,237+39.8% | Added |
| Jacobs Levy Equity Management, Inc | 1,033,763 | $519.5K | 0.00% | +1,033,763 | New |
| Northern Trust Corp | 1,274,492 | $640.4K | 0.00% | −810.0% | Reduced |
| Renaissance Technologies LLC | 2,283,072 | $1.15M | 0.00% | +2,085,972+1,058.3% | Added |
| DAFNA Capital Management LLC | 2,511,374 | $1.26M | 0.32% | +1,160,666+85.9% | Added |
| State Street Corp | 2,674,512 | $1.34M | 0.00% | +66,160+2.5% | Added |
| Geode Capital Management, LLC | 3,690,486 | $1.85M | 0.00% | +11,206+0.3% | Added |
| Alyeska Investment Group, L.P. | 3,947,369 | $1.98M | 0.01% | +3,947,369 | New |
| Raffles Associates LP | 5,492,088 | $2.76M | 2.97% | +984,307+21.8% | Added |
| Defender Capital, LLC. | 5,963,348 | $3.00M | 1.10% | +961,150+19.2% | Added |
| Perceptive Advisors LLC | 7,236,843 | $3.64M | 0.10% | +7,236,843 | New |
| Vanguard Group Inc | 8,632,928 | $4.34M | 0.00% | +31,933+0.4% | Added |
| BlackRock, Inc. | 10,094,677 | $5.07M | 0.00% | +174,877+1.8% | Added |
| Broadwood Capital Inc | 41,666,255 | $20.9M | 1.64% | 00.0% | Unchanged |
| Logos Global Management LP | 0 | $0 | 0.00% | −5,000,000−100.0% | Sold out |
| Long Focus Capital Management, LLC | 0 | $0 | 0.00% | −215,000−100.0% | Sold out |
| Manufacturers Life Insurance Company, The | 0 | $0 | 0.00% | −57,953−100.0% | Sold out |
| D. E. Shaw & Co., Inc. | 0 | $0 | 0.00% | −25,584−100.0% | Sold out |
| Pine Valley Investments Ltd Liability Co | 0 | $0 | 0.00% | −18,000−100.0% | Sold out |
| Straight Path Wealth Management | 0 | $0 | 0.00% | −16,200−100.0% | Sold out |
| Madrona Financial Services, LLC | 0 | $0 | 0.00% | −15,000−100.0% | Sold out |
| Founders Capital Management | 0 | $0 | 0.00% | −15,000−100.0% | Sold out |
| Two Sigma Securities, LLC | 0 | $0 | 0.00% | −13,941−100.0% | Sold out |
| Engineers Gate Manager LP | 0 | $0 | 0.00% | −11,458−100.0% | Sold out |
| Group One Trading, L.P. | 0 | $0 | 0.00% | −745−100.0% | Sold out |
| Capital Performance Advisors LLP | 0 | $0 | 0.00% | −163−100.0% | Sold out |
| Newbridge Financial Services Group, Inc. | 0 | $0 | 0.00% | −5−100.0% | Sold out |
| Raymond James & Associates | – | – | – | – | Not filed |
| Raymond James Financial Services Advisors, Inc. | – | – | – | – | Not filed |
| Planning Capital Management Corp | – | – | – | – | Not filed |